Table 1 Demographics of subjects included in the study (NCyoung: subjects with normal cognition under the age of 60; HIV-NC: HIV-infected subjects with normal cognition; HAND: HIV-infected subjects with cognitive impairment; NColder: subjects with normal cognition at or over the age of 60; MCI-AD: subjects with mild cognitive impairment and CSF biomarkers consistent with Alzheimer’s disease). *p ≤ 0.003 vs. NCyoung.

From: Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder

 

NCyoung (n = 31)

HIV-NC (n = 27)

HAND (n = 14)

NColder (n = 44)

MCI/AD (n = 25)

Male (%)

21 (68%)

22 (82%)

11 (79%)

20 (45%)

12 (48%)

African American (%)

13 (42%)

24 (89%)*

12 (86%)*

19 (43%)

12 (48%)

Age (SD), yr

36.9 (11.1)

40.8 (8.7)

38.0 (10.0)

71.1 (6.4)*

72.0 (11.1)*

Education (SD), yr

15.0 (2.4)

13.3 (2.5)

13.0 (2.2)

16.8 (2.4)*

16.7 (2.6)

Age of diagnosis (SD), yr

N.A

31.2 (6.5)

27.3 (15.0)

N.A

N.A

Disease duration (SD), yr

N.A

9.4(8.8)

10.2 (9.4)

N.A

N.A

Time since last cART (SD), mo

N.A.

14.9 (13.5)

12.6 (11.1)

N.A.

N.A.

Log10(plasma viral load)

N.D.

4.46 (0.80)

5.12 (0.85)

N.D.

N.D.

Log10(CSF viral load)

N.D.

2.97 (1.05)

3.28 (1.03)

N.D.

N.D.

CSF AD biomarkers (SD)

   Aβ42, pg/mL

238 (144)

176 (100)

139 (111)*

262 (124)

83 (39)*

   t-Tau, pg/mL

28.6 (13.3)

25.6 (12.0)

22.1 (10.1)

51.4 (25.8)*

71.5 (48.5)*

   p-Tau181, pg/mL

12.7 (4.0)

9.6 (3.9)

8.7 (5.2)*

18.8 (9.5)*

24.4 (14.2)*

CSF cytokines (SD)

   IL-8, pg/mL

66 (17)

113 (49)*

79 (20)

92 (27)*

79 (23)

   IP-10, ng/mL

2.5 (3.1)

11.5 (5.9)*

10.7 (6.3)*

4.2 (2.3)

3.2 (1.4)

   Fractalkine, pg/mL

142 (37)

177 (33)*

171 (26)*

73 (12)*

73 (13)*

   TNF-α, pg/mL

1.8 (0.9)

4.5 (3.3)*

4.7 (4.5)*

2.2 (0.8)

2.1 (0.9)

   MDC, pg/mL

86 (46)

194 (229)*

123 (124)*

175 (78)*

189 (101)*

   IL-10, pg/mL

5.2 (2.7)

8.8 (8.5)*

6.8 (4.6)

7.1 (1.6)

6.8 (1.9)

Back to article page